The present invention, in some embodiments thereof, relates to a multi-mode door and/or doorstop for a disposable drug delivery apparatus and, more particularly, but not exclusively, to a doorstop that prevents a door of a drug delivery apparatus from locking until a medicine cartridge is inserted.
U.S. Pat. No. 8,157,769 to Cabiri discloses a cartridge insertion assembly including apparatus with a pathway formed therein, a cartridge insertable into the pathway, the cartridge including a cartridge coupling element connectable to an activation mechanism disposed in the apparatus operative to cause a substance contained in the cartridge to be metered out of the cartridge, and a door pivoted to the apparatus that includes a door coupling element arranged with respect to the cartridge such that when the door is in a fully closed mode, the door coupling element couples the cartridge coupling element with a coupling element of the activation mechanism.
U.S. Pat. No. 7,749,194 to Edwards et al. discloses an auto-injector, which can comprise: a vial configured to store and/or contain an injectable medicament, the vial defining a vial longitudinal axis, and a housing comprising the vial. In various embodiments, the injectable medicament can be a medicine, medication, drug, pharmaceutical, prescriptive, agent, antidote, anti-venom, hormone, stimulant, vasodilator, anesthetic, and/or nutritional supplement that is substantially ready for injection.
U.S. Pat. No. 7,588,559 to Aravena et al. discloses an intraosseous injection device including a tool having a distal portion, a proximal portion, and a solution dispensing opening. The distal portion has one or more cutting surfaces. The tool can be coupled with a protective carrier. The tool can be rotatably coupled to a tool actuation mechanism. A housing has a distal end and a proximal end. The housing releasably receives a solution cartridge containing a solution. A solution dispensing mechanism dispenses solution from the solution cartridge. A gripping member grips a proximal portion of the tool. A rotation device rotates the gripping member and thereby rotates the tool about an axis. The proximal portion of the tool connects directly to the solution cartridge such that solution from the cartridge can be delivered through the solution dispensing opening. The tool is configured to rotate relative to the solution cartridge.
United States Patent Application 2009/0093793 to Gross et al. discloses an apparatus for administering a substance to a subject. A vial contains the substance, an inner surface of the vial being shaped to define a protrusion therefrom. A stopper within the vial is slidably coupled to the vial. A first threaded element is (a) rotatable and (b) substantially immobile proximally with respect to the vial during rotation of the first threaded element. A second threaded element is threadedly coupled to the first threaded element. The protrusion impedes rotation of the second threaded element with respect to the vial. The distal end of the second threaded element remains proximal to a distal end of the stopper during rotation of the first threaded element. The first threaded element, by rotating, linearly advances the stopper and the second threaded element toward a distal end of the vial. Other embodiments are also described.
United States Patent Application 2008/0097381 to Moberg et al. discloses a delivery device including, a durable housing portion and a separable disposable portion that selectively engage and disengage from each other. The disposable housing portion secures to the patient-user and may be disposed of after it has been in use for a prescribed period. Components that normally come into contact with a patient-user or with infusion medium are supported by the disposable housing portion, while the durable housing portion supports other components such as electronics and a drive device. A reservoir is supported by the disposable housing portion and has a moveable plunger that operatively couples to the drive device, when the disposable and durable housing portions are engaged.
Additional background art includes U.S. Pat. No. 5,858,001 to Tsals and U.S. Pat. No. 7,967,795 to Cabiri.
According to an aspect of some embodiments of the present invention there is provided an insertion assembly for a cartridge in a drug delivery apparatus including: an apparatus housing; a channel for insertion of the cartridge formed in the housing; a door to an opening of the channel; a doorstop including a flange and an extension, and wherein the doorstop has two modes, an obstructing mode wherein the flange obstructs closing of the door and wherein the extension extends to a path of insertion of the cartridge into the channel and a non-obstructing mode wherein the door may close unobstructed by the doorstop and wherein, when the cartridge is inserted into the channel, the cartridge engages the extension moving the doorstop to the non-obstructing mode.
According to some embodiments of the invention, the doorstop includes a base, and the flange is held above the base in the obstructing mode, such that when the door rests on the flange the door protrudes from the housing by a predetermined distance.
According to some embodiments of the invention, the doorstop includes a rotating base and wherein the doorstop rotates from the obstructing mode to the non-obstructing mode.
According to some embodiments of the invention, the doorstop includes a sliding base and wherein the doorstop slides from the obstructing mode to the non-obstructing mode.
According to some embodiments of the invention, in the non-obstructing mode the doorstop blocks an exit of the channel, impeding removal of the cartridge from the channel.
According to some embodiments of the invention, the cartridge includes a flange and the engaging is by the cartridge flange.
According to some embodiments of the invention, the door has at least three states: a fully open state wherein the door clears an opening to the channel enough to allow insertion of a cartridge into the channel and wherein in the fully open state the door protrudes from the apparatus, a transport state wherein the door at least partially obstructs the opening and wherein in the transport state the door protrudes from the apparatus less than the protruding during the open state, and a fully closed state wherein the door obstructs the opening enough to prevent both insertion and removal of the cartridge through the opening; and wherein the door moves freely between the transport state and the fully open state.
According to some embodiments of the invention, the door includes a notch on an inside surface thereof, the notch supporting a projection from the cartridge when the door is in the closed state.
According to some embodiments of the invention, the door is mounted on a pivot and wherein the door pivots between the states.
According to some embodiments of the invention, the door includes a coupler, the coupler located such that in when the door is in the closed state the coupler couples a movable element of the cartridge to a motive element in apparatus.
According to some embodiments of the invention, the assembly further includes a latch and wherein, in the fully closed state the latch reversibly latches the door.
According to some embodiments of the invention, the assembly further includes a latch and wherein, in the closed state the latch permanently locks the door.
According to some embodiments of the invention, in the permanently locked state the door is latched to the doorstop in the non-obstructing mode.
According to some embodiments of the invention, the assembly further includes a hook mounted to the doorstop and wherein latching is to the hook.
According to some embodiments of the invention, the assembly further includes a stabilizer maintaining the doorstop in the obstructing mode, until a force greater than a threshold value moves the doorstop into the non-obstructing mode.
According to an aspect of some embodiments of the present invention there is provided a method of preparing a drug delivery apparatus for use the apparatus including a housing having a insertion channel and a cartridge configured for insertion into the channel and a door to the channel including: supplying the apparatus in a transport state wherein the door at least partially blocks the channel and wherein a doorstop is in a obstructing mode, obstructing movement of the door into a fully closed state; opening the door; inserting the cartridge and thereby; shifting the doorstop from the obstructing mode into a non-obstructing mode; closing the door, and latching the door.
According to some embodiments of the invention, opening the door increases a protrusion of the door from the housing.
According to some embodiments of the invention, the method further includes supporting a projection from the cartridge on the door when the door is in the closed state.
According to some embodiments of the invention, the opening and closing include pivoting the door in a plane of an opening of the channel.
According to some embodiments of the invention, the method further includes interconnecting a movable element of the cartridge to a motive element of the apparatus by via the closing, wherein the interconnecting is via a coupler mounted to the door.
According to some embodiments of the invention, the latching is temporary.
According to some embodiments of the invention, the method further includes supporting the door on the doorstop in the transport state.
According to some embodiments of the invention, the method further includes impeding by the doorstop of a removal of the cartridge from the channel when the doorstop is in the non-obstructing mode.
According to some embodiments of the invention, the doorstop includes a pin, and wherein upon closing the door with the cartridge inserted, the cartridge displaces the pin.
According to some embodiments of the invention, the latching is to the doorstop. Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
The present invention, in some embodiments thereof, relates to a multi-position door and doorstop for a disposable drug delivery apparatus and, more particularly, but not exclusively, to a doorstop that prevents a door of a drug delivery apparatus from locking until a medicine cartridge is inserted.
Overview
3 State Door
An aspect of some embodiments of the current application is a doorstop to a drug delivery apparatus that encourages a user of the apparatus to perform the proper usage steps in the proper order. For example, a user may be expected to receive an injector in a transport state, open it to an open state, insert a cartridge, and/or close the cartridge before operation. In some cases the user of the apparatus may be anxious, distracted and/or confused and/or disabled. A doorstop may optionally be provided to make the performing the proper steps in the proper order intuitive, simple and/or easy. The doorstop may also deter the user from performing an incorrect action and/or the doorstop may also deter the user from performing an action in an improper order.
Transport State
In some embodiments a delivery apparatus may be supplied to a patient in a transport state configured for transport and/or storage. In the transport state the apparatus may optionally be configured to be compact and/or to resist damage for example from rough handling. For example, in a transport state, a door of the delivery apparatus may be configured to not protrude from the housing of the apparatus and/or to protrude very little from the housing of the apparatus. A protruding part may sometimes cause an apparatus to be non-compact. A protruding part may sometimes be vulnerable to damage. For example, in the transport state, the door may optionally protrude from the housing of the delivery apparatus less than 4 mm and/or less than 2 mm. As used herein, the length of a protrusion of a door from an apparatus means the distance from the point on the door furthest from the apparatus to the closest point on the apparatus.
In some embodiments, in the transport state, a doorstop may be provided in an obstructing mode. In the obstructing mode, the doorstop may obstruct closing of the door. For example, in the obstructing mode, the doorstop may obstruct premature closing of the door for example due to vibrations and/or rough handling and/or inadvertent closing by a confused patient.
In some embodiments, prior to use of a delivery apparatus, a user may be open a door. For example, in the transport mode the door may fully and/or partially block a cartridge channel. Optionally in order before inserting a cartridge into the channel, the user may open the door. The door may optionally move easily and/or intuitively from the transport state to an open state. For example, in the transport state the door may protrude slightly from the apparatus. In the transport state, the door may for example protrude between 0.1 and 0.8 cm. The slight protrusion of the door may help an anxious and/or confused patient intuitively understand how to open the door.
Open State
In some embodiments, in the open state, a door may clear an opening of a cartridge channel enough to insert a cartridge into the opening. Optionally, in the open state, the door may protrude significantly from the apparatus, for example the door may protrude a distance ranging between 2 and 4 cm. In the open mode the door may protrude for example between 5 and 40 times as much as it protrudes in the transport state.
In some embodiments, while the apparatus is in the open state, the user will insert a cartridge into the cartridge channel. For example, inserting the cartridge may cause a doorstop to move non-obstructing mode. Optionally the doorstop may move into the non-obstructing mode when at least a majority of the cartridge has been inserted into the channel. For example, the doorstop may move into the non-obstructing mode when the cartridge has been inserted to a degree ranging been 60% and 100% of its fully inserted position. In the non-obstructing mode, the doorstop may optionally impede removal of the cartridge from the channel. For example insertion of the cartridge may optionally cause priming of the apparatus, for example by puncturing a septum. Optionally it may be undesirable to remove the cartridge after insertion.
Closed State
In some embodiments, moving the doorstop into the non-obstructing mode may allow the door to close and/or permanently lock. In a closed state, the door may optionally inhibit removal, corruption, misuse, and/or reuse of the cartridge and/or the delivery apparatus. Alternatively and/or additionally in a closed state the door may inhibit dirt and or infecting organisms from entering the delivery apparatus. Alternatively and/or additionally in the closed state the door may inhibit a person from being injured by the delivery apparatus. Alternatively or additionally, in a closed state the door may protect the delivery apparatus from tampering and/or insertion of foreign objects. Optionally, the apparatus may be configured non-operable until the door is closed.
In some embodiments, a doorstop may prevent opening of a door when the door is closed after insertion of a cartridge. For example, a doorstop may be latch the door to the housing of the apparatus and/or a latch may attach to the doorstop when the doorstop is in the non-obstructing mode.
In some embodiments, the housing of a drug delivery apparatus may include a supporting structure. The supporting structure may optionally engage the door and/or support the door when the door is in the closed state and/or the transport state and/or a permanently locked state.
In some embodiments, a coupler may be mounted on the door. The coupler may optionally transmit power from the drug delivery apparatus to the cartridge when the door is in a closed mode. Optionally, the power may be used to deliver the drug. Optionally, in a closed state and/or locked state, the door may support a component of the drug delivery apparatus. For example, the door may optionally include a notch to support a projection from said cartridge. For example, the door may support a rear end of the cartridge. Optionally the projection may revolve in the notch. Optionally, when in a closed state and/or in a locked state, the door may serve as a counter force. For example, the door may act as a counter force for pushing a plunger into a syringe to deliver the drug.
In some embodiments the door may pivot. For example, the door may pivot in the plane of the opening of the cartridge channel. Alternatively or additionally, the door may slide. For example, the door may slide in the plane of the opening. Alternatively or additionally, the door may swing. For example, the door may swing on a hinge into and out of the plane of the opening.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Method of Preparing a Drug Delivery Apparatus
Referring now to
In some embodiments, the user may transport 106 the apparatus (for example a patient may take the apparatus home) and/or store the apparatus. For the sake of transport 106 and/or storage, the apparatus may be optionally placed in a transport state without large projecting parts that take up space and/or are vulnerable to breakage. For example, in the transport mode, the door may rest on a doorstop so that the door is almost closed. Alternatively or additionally, the apparatus may be transported and/or stored before being given to the patent.
Before use, the user may optionally prepare 104 the apparatus for use. For example, the user may take the apparatus out 107 from its protective blister. In some cases, when opening a blister to take out 107 the apparatus a user may apply significant force. The transport mode of the apparatus may optionally be configured to prevent breakage of the apparatus while opening the blister.
In some embodiments, after taking out 107 the apparatus from the blister, a user may open 108 a door of a cartridge channel. Optionally the user may be a patient. Typically a patient may be anxious, confused, feeling sick, have impaired movement, have impaired senses and/or be in pain. Optionally, a delivery apparatus may be designed to allow easy, safe preparation. For example, preparation may be intuitive and/or include safeguards against improper action. Optionally preparation will not include steps, forces and/or noises that may confuse the patient into thinking that there has been a malfunction. Optionally, the apparatus may include reassuring noises and/or forces that reassure the user that he has taken the correct action and/or that the apparatus is working properly. Optionally, opening the door may be an intuitive process. For example, the door may open 108 with minimal smooth application of force (without giving the user the feeling that he is forcing and/or breaking something). Optionally, a user may be inhibited from performing an act that is not correct and/or not in the correct order. For example, a doorstop may prevent closing 112 of the door before insertion 109 of the cartridge.
In some embodiments, after opening 108 the door, a cartridge is inserted 109 into a channel in the apparatus. Optionally, inserting 109 the cartridge will automatically release 110 the doorstop. For example, the doorstop may be released 110 from the obstructing mode wherein the doorstop obstructs closing 112 of the door to a non-obstructing mode, wherein the door may be closed 112 freely.
In some embodiments, after inserting 109 the cartridge, the user closes 112 the door to the cartridge channel. Optionally, closing 112 the door may enable 111 delivery of the drug. For example, the door may include a coupler. Optionally, when the door is closed the coupler may connect a drive element to a motive element, enabling 111 delivery. Optionally, when the doorstop is in the non-obstructing position, closing 112 the door will cause the door to permanently lock 113. Alternatively or additionally, locking 113 may occur separately from closing 112 the door. For example, locking 113 may occur at some time after closing 112.
In some embodiments, once the door is closed 112 and locked 113 with the cartridge inserted 109 then the apparatus may be used 114. Optionally, after use 114, the sealed apparatus may be safely disposed of 116 for example in the municipal garbage.
Schematic Illustration of an Exemplary Embodiment of a Drug Delivery Apparatus and Doorstop
Referring now to the figures,
The transport state, for example as illustrated in
In some embodiments, before employing apparatus 219, a user may open door 220 into an open configuration, for example as illustrated in
In some embodiments, after inserting cartridge 224, the user may close door 220, putting apparatus 219 into a closed mode, for example as illustrated in
States of a Drug Delivery Apparatus
Referring now to the figures,
In some embodiments, a drug delivery apparatus may be supplied to a user in a transport state 374′ with the doorstop in an obstructing mode 373. The user may optionally open the door to an open state 372′. The door may optionally move freely between transport state 374′ and open state 372′. With the doorstop in the obstructing mode 373, the apparatus may optionally be obstructed from moving to a closed state 376′. With the doorstop in the obstructing mode, the apparatus may optionally be obstructed from moving to a locked state 378′. Optionally, when the apparatus is in transport state 374′ and/or open state 372′ the apparatus may be prevented from delivering the drug.
In some embodiments, if by some means, a user forces the apparatus into closed state 376′ while the doorstop is in obstructing mode 373, the door may be able to return to transport state 374′ and/or open state 372′. Optionally, with the doorstop in the obstructing mode 373, the door may return spontaneously from closed state 376′ to transport state 374′ and/or open state 372′. Alternatively or additionally, there may be a temporary latch which can be released by the user to return the door from closed state 376′ to transport state 374′.
In some embodiments, a cartridge may be inserted into the apparatus. For example, the cartridge may be inserted while the apparatus is in the open state. Optionally, inserting a cartridge into the delivery apparatus may move 370 the doorstop from obstructing mode 373 to a non-obstructing mode 379. Optionally, when the doorstop is in non-obstructing mode 379, removal of the cartridge may be impeded.
In some embodiments, the doorstop may be stable and/or bi-stable. For example, the doorstop may be prevented from moving spontaneously from the obstructing mode 373 to non-obstructing mode 379. Alternatively or additionally it may be prevented from moving spontaneously from non-obstructing mode 379 to obstructing mode 373. Optionally, movement of doorstop may be one direction, for example once in the non-obstructing mode 379 it may remain there permanently and not return to obstructing mode 373. Alternatively or additionally the doorstop may not be stabilized.
With the doorstop in the non-obstructing mode 379, the apparatus may optionally be able to move from open state 372″ and/or transport state 374″ to a closed state 376″. With the doorstop in the non-obstructing mode 379, the apparatus may optionally be able to move to a locked state 378″. Optionally, unless the apparatus is in the closed state 376″ and/or locked state 378″ the apparatus may be prevented from delivering the drug. Optionally, when the apparatus is in the closed state 376″ and/or locked state 378″ the apparatus may deliver the drug.
In some embodiments, after a user place the apparatus into closed state 376″ while the doorstop is in non-obstructing mode 379. Optionally, the door may be able to return from closed state 376″ to transport state 374″ and/or open state 372″. Alternately or additionally, with the doorstop in the non-obstructing mode 379, the doorstop may obstruct the door from returning from closed state 376″ and/or there may be a temporary latch which can be released by the user to return the door from closed state 376″ to transport state 374″. While the doorstop is in non-obstructing mode 379, the door may optionally be moved to a permanently locked state 378″.
Detailed Exemplary Embodiment of a Drug Delivery Apparatus and Doorstop
Referring now to the figures,
In some embodiments, inserting a cartridge into the apparatus switches the doorstop into a non-obstructing mode. Optionally, the switching is by rotating the doorstop. In the non-obstructing mode, the doorstop optionally impedes removal of the cartridge. In the non-obstructing mode, the door is optionally allowed to close and permanently lock.
An optional coupling may be mounted to the door. When the door is in the closed and/or locked state, the coupling may link a motive element of the drug delivery apparatus to a movable element of the cartridge. Optionally, when linked to the motive element, the movable element may instigate delivery of the drug.
In some embodiments, when the door is closed it may serve as a counter force for an expanding plunger to deliver the medicine. Alternatively, when permanently closed, the door may protect the apparatus from tampering and/or protect the apparatus from reuse and/or misuse and/or protect the user for injury from internal parts of the apparatus.
Referring now to the figures,
In some embodiments, (for example as illustrated in
In some embodiments, a stabilizer 422 may provide bi-stability to doorstop 418. For example, in
Referring now to the figures,
In some embodiments, doorstop 418 may include a spacer 442. For example, when doorstop is in the non-obstructing mode (for example see
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
In some embodiments, cartridge 624 is in the form of a syringe barrel. Optionally, cartridge 624 includes a flange 626. Flange 626 may be, for example, similar to flanges on standard syringes. For example, flange 626 may be at or towards the rear end (opposite the tip) of the syringe.
In some embodiments, an optional telescoping assembly 692 may be supplied. Assembly 692 may optionally be fitted to the open end of cartridge 624. Telescoping assembly 692 may optionally be driven by a movable element 682 which may, for example, include a gear. Optionally, the gear revolves telescoping assembly 692. Optionally when door 420 is closed, coupler 584 connects movable element 682 to a motive element 686 (for example see
Referring now to the figures,
In some embodiments, the sides of cartridge 624 optionally do not contact doorstop 418 while cartridge 624 is being inserted. This may have a few advantages. For example, if cartridge 624 can be removed from the partially inserted position of
Referring now to the figures,
In some embodiments, a flange 626 will contact doorstop 418 to rotate it and switch it to the non-obstructing state. Flange 626 may optionally shield movable element 682 from contact and/or damage from doorstop 418. For example, flange 626 moves doorstop 418 into the non-obstructing mode when the tip of cartridge 624 has been inserted to about 60% its final position.
In some embodiments, door 420 may include a feature to engage a structural support in a closed position. The structural support may, for example be a part of the delivery apparatus housing 419. For example, door 420 may include an indentation 827 that engages with rear support 446 upon when door 420 is in a closed state. Optionally, indentation 827 may fully and/or partially engage rear support 446 when door 420 is in the transport state. Engaging rear support 446 strengthens door 420 for example to prevent breakage by outside forces and/or to prevent door 420 from passing behind flange 444 circumventing doorstop 418 and/or to provide support for hub 599, projection 688 and/or telescoping assembly 692.
Referring now to the figures,
Referring now to the figures,
An Exemplary Transmission Mechanism for an Exemplary Embodiment of a Drug Delivery Apparatus
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
In some embodiments, when door 420 is in a closed state a supporting structure may engage and/or support door 420. For example, in
Referring now to the figures,
Alternative Embodiments of a Doorstop for a Drug Delivery Apparatus
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
Referring now to the figures,
In some embodiments, a user will be prevented from removing a cartridge when doorstop 1518 is in the non-obstructing mode. An attempt to remove the cartridge may optionally be blocked without disabling the drug delivery apparatus. For example, an attempt to remove a cartridge (for example cartridge 624) when doorstop 1518 is in the non-obstructing mode will optionally cause the cartridge flange (for example flange 626) to collide with flange 1544. After collision with flange 1544, further attempts remove the cartridge will optionally rotate doorstop 1518 about 45 degrees clockwise until spacer 1542 contacts the body of the cartridge. Optionally at the point where spacer 1542 contacts the body of the cartridge, doorstop 1518 may be prevented from further clockwise rotation. Optionally at the point where spacer 1542 contacts the body of the cartridge, flange 1544 may still be blocking the rear of the cartridge. Optionally at the point where spacer 1542 contacts the body of the cartridge, flange 1544 may not obstruct closing of door 420. Optionally at the point where spacer 1542 contacts the body of the cartridge, door 420 may be closed and the apparatus activated, but removal of the cartridge will optionally be prevented.
Referring now to the figures,
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find support in the following examples.
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.
Force Graphs
Referring now to the Figures,
Referring now to the Figures,
Referring now to the Figures,
Referring now to the Figures,
Referring now to the Figures,
Referring now to the Figures,
Caveats
As used herein the term “about” refers to ±5%
The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.
The term “consisting of” means “including and limited to”.
The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
Number | Name | Date | Kind |
---|---|---|---|
1795630 | Wilson | Mar 1931 | A |
2860635 | Wilburn | Nov 1958 | A |
3203269 | Perrine | Aug 1965 | A |
3212685 | Swan et al. | Oct 1965 | A |
3794028 | Mueller et al. | Feb 1974 | A |
3994295 | Wulff | Nov 1976 | A |
4195636 | Behnke | Apr 1980 | A |
4218724 | Kaufman | Aug 1980 | A |
4273122 | Whitney et al. | Jun 1981 | A |
4300554 | Hessberg et al. | Nov 1981 | A |
4403987 | Gottinger | Sep 1983 | A |
4435173 | Siposs et al. | Mar 1984 | A |
4465478 | Sabelman et al. | Aug 1984 | A |
4565543 | Bekkering et al. | Jan 1986 | A |
4585439 | Michel | Apr 1986 | A |
4599082 | Grimard | Jul 1986 | A |
4601702 | Hudson | Jul 1986 | A |
4685903 | Cable et al. | Aug 1987 | A |
4689043 | Bisha | Aug 1987 | A |
4698055 | Sealfon | Oct 1987 | A |
4810215 | Kaneko | Mar 1989 | A |
4850966 | Grau et al. | Jul 1989 | A |
4867743 | Vaillancourt | Sep 1989 | A |
4886499 | Cirelli et al. | Dec 1989 | A |
4919596 | Slate et al. | Apr 1990 | A |
4929241 | Kulli | May 1990 | A |
4950246 | Muller | Aug 1990 | A |
D322671 | Szwarc | Dec 1991 | S |
5090877 | D'Silva | Feb 1992 | A |
5109850 | Blanco et al. | May 1992 | A |
5112317 | Michel | May 1992 | A |
5131816 | Brown et al. | Jul 1992 | A |
5190521 | Hubbard et al. | Mar 1993 | A |
5254096 | Rondelet et al. | Oct 1993 | A |
5300045 | Plassche, Jr. | Apr 1994 | A |
5342313 | Campbell et al. | Aug 1994 | A |
5348544 | Sweeney et al. | Sep 1994 | A |
5364364 | Kasvikis | Nov 1994 | A |
5366498 | Brannan et al. | Nov 1994 | A |
5383865 | Michel | Jan 1995 | A |
5445621 | Poli | Aug 1995 | A |
5478315 | Brothers et al. | Dec 1995 | A |
5482446 | Williamson et al. | Jan 1996 | A |
5496274 | Graves et al. | Mar 1996 | A |
5501665 | Jhuboo et al. | Mar 1996 | A |
5505709 | Funderburk | Apr 1996 | A |
5562686 | Sauer et al. | Oct 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5616132 | Newman | Apr 1997 | A |
5643218 | Lynn et al. | Jul 1997 | A |
5645955 | Maglica | Jul 1997 | A |
5647853 | Feldmann et al. | Jul 1997 | A |
5662678 | Macklin | Sep 1997 | A |
5672160 | Osterlind et al. | Sep 1997 | A |
5690618 | Smith et al. | Nov 1997 | A |
D393314 | Meisner et al. | Apr 1998 | S |
5766186 | Faraz et al. | Jun 1998 | A |
5779676 | Kriesel | Jul 1998 | A |
5795675 | Maglica | Aug 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5807375 | Gross et al. | Sep 1998 | A |
5814020 | Gross | Sep 1998 | A |
5830187 | Kriesel | Nov 1998 | A |
5836920 | Robertson | Nov 1998 | A |
5848991 | Gross et al. | Dec 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5858001 | Tsals et al. | Jan 1999 | A |
5858008 | Capaccio | Jan 1999 | A |
5868710 | Battiato et al. | Feb 1999 | A |
5931814 | Alex et al. | Aug 1999 | A |
5941850 | Shah et al. | Aug 1999 | A |
5948392 | Haslwanter et al. | Sep 1999 | A |
5954697 | Srisathapat | Sep 1999 | A |
5957895 | Sage et al. | Sep 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5993423 | Choi | Nov 1999 | A |
6004297 | Steenfeldt-Jensen et al. | Dec 1999 | A |
6033245 | Yamkovoy | Mar 2000 | A |
6033377 | Rasmussen et al. | Mar 2000 | A |
6064797 | Crittendon et al. | May 2000 | A |
6074369 | Sage et al. | Jun 2000 | A |
6186982 | Gross et al. | Feb 2001 | B1 |
6200289 | Hochman et al. | Mar 2001 | B1 |
6200296 | Dibiasi et al. | Mar 2001 | B1 |
6224569 | Brimhall | May 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6277095 | Kriesel et al. | Aug 2001 | B1 |
6277098 | Klitmose et al. | Aug 2001 | B1 |
6277099 | Strowe et al. | Aug 2001 | B1 |
6287283 | Ljunggreen et al. | Sep 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6302633 | Poe | Oct 2001 | B1 |
6336729 | Pavelle et al. | Jan 2002 | B1 |
6345968 | Shupe | Feb 2002 | B1 |
6377848 | Garde et al. | Apr 2002 | B1 |
6391005 | Lum et al. | May 2002 | B1 |
6423029 | Elsberry | Jul 2002 | B1 |
6423036 | Van Huizen | Jul 2002 | B1 |
D465026 | May et al. | Oct 2002 | S |
6458102 | Mann et al. | Oct 2002 | B1 |
6485461 | Mason et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6500150 | Gross et al. | Dec 2002 | B1 |
6503231 | Prausnitz et al. | Jan 2003 | B1 |
6511336 | Turek et al. | Jan 2003 | B1 |
6517517 | Farrugia et al. | Feb 2003 | B1 |
D471274 | Diaz et al. | Mar 2003 | S |
D471983 | Hippolyte et al. | Mar 2003 | S |
6558351 | Steil et al. | May 2003 | B1 |
6589229 | Connelly et al. | Jul 2003 | B1 |
6595956 | Gross et al. | Jul 2003 | B1 |
6595960 | West et al. | Jul 2003 | B2 |
6599272 | Hjertman | Jul 2003 | B1 |
6645181 | Lavi et al. | Nov 2003 | B1 |
6652482 | Hochman | Nov 2003 | B2 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6673033 | Sciulli et al. | Jan 2004 | B1 |
6679862 | Diaz et al. | Jan 2004 | B2 |
6689118 | Alchas et al. | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6722916 | Buccinna et al. | Apr 2004 | B2 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6749587 | Flaherty | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6786890 | Preuthun et al. | Sep 2004 | B2 |
6800071 | McConnell et al. | Oct 2004 | B1 |
6805687 | Dextradeur et al. | Oct 2004 | B2 |
6824529 | Gross et al. | Nov 2004 | B2 |
6843782 | Gross et al. | Jan 2005 | B2 |
6854620 | Ramey | Feb 2005 | B2 |
6905298 | Haring | Jun 2005 | B1 |
6908452 | Diaz et al. | Jun 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6997727 | Legrady et al. | Feb 2006 | B1 |
7001360 | Veasey et al. | Feb 2006 | B2 |
7034223 | Fan et al. | Apr 2006 | B2 |
7048715 | Diaz et al. | May 2006 | B2 |
7060054 | Nissels | Jun 2006 | B2 |
7060059 | Keith et al. | Jun 2006 | B2 |
7097637 | Triplett et al. | Aug 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
D544092 | Lewis | Jun 2007 | S |
7225694 | Said | Jun 2007 | B2 |
7247149 | Beyerlein | Jul 2007 | B2 |
7250037 | Shermer et al. | Jul 2007 | B2 |
7267669 | Staunton et al. | Sep 2007 | B2 |
7291132 | DeRuntz et al. | Nov 2007 | B2 |
7291159 | Schmelzeisen-Redeker et al. | Nov 2007 | B2 |
7303549 | Flaherty et al. | Dec 2007 | B2 |
7344385 | Chen | Mar 2008 | B2 |
7364570 | Gerondale et al. | Apr 2008 | B2 |
7390314 | Stutz, Jr. et al. | Jun 2008 | B2 |
7407493 | Cane′ | Aug 2008 | B2 |
D578210 | Muta et al. | Oct 2008 | S |
7455663 | Bikovsky | Nov 2008 | B2 |
7465290 | Reilly | Dec 2008 | B2 |
7488181 | van Haaster | Feb 2009 | B2 |
7497842 | Diaz et al. | Mar 2009 | B2 |
7501587 | English | Mar 2009 | B2 |
7503786 | Kato et al. | Mar 2009 | B2 |
7530964 | Lavi et al. | May 2009 | B2 |
7547281 | Hayes et al. | Jun 2009 | B2 |
7565208 | Harris et al. | Jul 2009 | B2 |
7569050 | Moberg et al. | Aug 2009 | B2 |
D600341 | Loerwald | Sep 2009 | S |
7585287 | Bresina et al. | Sep 2009 | B2 |
7588559 | Aravena et al. | Sep 2009 | B2 |
7589974 | Grady et al. | Sep 2009 | B2 |
D602155 | Foley et al. | Oct 2009 | S |
D602586 | Foley et al. | Oct 2009 | S |
D604835 | Conley | Nov 2009 | S |
7628770 | Ethelfeld | Dec 2009 | B2 |
7628772 | McConnell et al. | Dec 2009 | B2 |
7628782 | Adair et al. | Dec 2009 | B2 |
7637891 | Wall | Dec 2009 | B2 |
7637899 | Woolston et al. | Dec 2009 | B2 |
7641649 | Moberg et al. | Jan 2010 | B2 |
7660627 | McNichols et al. | Feb 2010 | B2 |
7678079 | Shermer et al. | Mar 2010 | B2 |
7682338 | Griffin | Mar 2010 | B2 |
7686787 | Moberg et al. | Mar 2010 | B2 |
7699829 | Harris et al. | Apr 2010 | B2 |
7699833 | Moberg et al. | Apr 2010 | B2 |
7704088 | Sakamoto | Apr 2010 | B2 |
7704227 | Moberg et al. | Apr 2010 | B2 |
7704229 | Moberg et al. | Apr 2010 | B2 |
7704231 | Pongpairochana et al. | Apr 2010 | B2 |
7708717 | Estes et al. | May 2010 | B2 |
7713238 | Mernoe | May 2010 | B2 |
7713240 | Istoc et al. | May 2010 | B2 |
7717913 | Novak et al. | May 2010 | B2 |
7722574 | Toman et al. | May 2010 | B2 |
7736344 | Moberg et al. | Jun 2010 | B2 |
7744589 | Mounce et al. | Jun 2010 | B2 |
7749194 | Edwards et al. | Jul 2010 | B2 |
7776030 | Estes et al. | Aug 2010 | B2 |
7780637 | Jerde et al. | Aug 2010 | B2 |
7789857 | Moberg et al. | Sep 2010 | B2 |
7801599 | Young et al. | Sep 2010 | B2 |
7806868 | De Polo et al. | Oct 2010 | B2 |
7828528 | Estes et al. | Nov 2010 | B2 |
7837659 | Bush, Jr. et al. | Nov 2010 | B2 |
7846132 | Gravesen et al. | Dec 2010 | B2 |
7854723 | Hwang et al. | Dec 2010 | B2 |
7857131 | Vedrine | Dec 2010 | B2 |
7879025 | Jacobson et al. | Feb 2011 | B2 |
7918825 | O'Connor et al. | Apr 2011 | B2 |
7935104 | Yodfat et al. | May 2011 | B2 |
7935105 | Miller et al. | May 2011 | B2 |
7938803 | Mernoe et al. | May 2011 | B2 |
7955305 | Moberg et al. | Jun 2011 | B2 |
7967784 | Pongpairochana et al. | Jun 2011 | B2 |
7967795 | Cabiri | Jun 2011 | B1 |
7981105 | Adair et al. | Jul 2011 | B2 |
7988683 | Adair et al. | Aug 2011 | B2 |
7993300 | Nyholm et al. | Aug 2011 | B2 |
7993301 | Boyd et al. | Aug 2011 | B2 |
7998111 | Moberg et al. | Aug 2011 | B2 |
8021357 | Tanaka et al. | Sep 2011 | B2 |
8025658 | Chong et al. | Sep 2011 | B2 |
8029469 | Ethelfeld | Oct 2011 | B2 |
8034019 | Nair et al. | Oct 2011 | B2 |
8038666 | Triplett et al. | Oct 2011 | B2 |
8057431 | Woehr et al. | Nov 2011 | B2 |
8057436 | Causey et al. | Nov 2011 | B2 |
8062253 | Nielsen et al. | Nov 2011 | B2 |
8066694 | Wagener | Nov 2011 | B2 |
D650079 | Presta et al. | Dec 2011 | S |
D650903 | Kosinski et al. | Dec 2011 | S |
8086306 | Katzman et al. | Dec 2011 | B2 |
D652503 | Cameron et al. | Jan 2012 | S |
8105279 | Mernoe et al. | Jan 2012 | B2 |
8114046 | Covino et al. | Feb 2012 | B2 |
8114064 | Alferness et al. | Feb 2012 | B2 |
8114066 | Naef et al. | Feb 2012 | B2 |
D657462 | Siroky | Apr 2012 | S |
8147446 | Yodfat et al. | Apr 2012 | B2 |
8152764 | Istoc et al. | Apr 2012 | B2 |
8152770 | Reid | Apr 2012 | B2 |
8152779 | Cabiri | Apr 2012 | B2 |
8152793 | Keinanen et al. | Apr 2012 | B2 |
8157693 | Waksmundzki | Apr 2012 | B2 |
8157769 | Cabiri | Apr 2012 | B2 |
8162674 | Cho et al. | Apr 2012 | B2 |
8162923 | Adams et al. | Apr 2012 | B2 |
8167841 | Teisen-Simony et al. | May 2012 | B2 |
8172591 | Wertz | May 2012 | B2 |
8172804 | Bikovsky | May 2012 | B2 |
8182462 | Istoc et al. | May 2012 | B2 |
8197444 | Bazargan et al. | Jun 2012 | B1 |
8206351 | Sugimoto et al. | Jun 2012 | B2 |
8221356 | Enggaard et al. | Jul 2012 | B2 |
8267921 | Yodfat et al. | Sep 2012 | B2 |
8287520 | Drew et al. | Oct 2012 | B2 |
8292647 | McGrath et al. | Oct 2012 | B1 |
8308679 | Hanson et al. | Nov 2012 | B2 |
8323250 | Chong et al. | Dec 2012 | B2 |
8372039 | Mernoe et al. | Feb 2013 | B2 |
8373421 | Lindegger et al. | Feb 2013 | B2 |
8409142 | Causey et al. | Apr 2013 | B2 |
8414557 | Istoc et al. | Apr 2013 | B2 |
8430847 | Mernoe et al. | Apr 2013 | B2 |
8465455 | Cabiri | Jun 2013 | B2 |
8469942 | Kow et al. | Jun 2013 | B2 |
8474332 | Bente, IV et al. | Jul 2013 | B2 |
8475408 | Mernoe et al. | Jul 2013 | B2 |
8479595 | Vazquez et al. | Jul 2013 | B2 |
8495918 | Bazargan et al. | Jul 2013 | B2 |
8496862 | Zelkovich et al. | Jul 2013 | B2 |
8512287 | Cindrich et al. | Aug 2013 | B2 |
8517987 | Istoc et al. | Aug 2013 | B2 |
8523803 | Favreau | Sep 2013 | B1 |
8556856 | Bazargan et al. | Oct 2013 | B2 |
8562364 | Lin et al. | Oct 2013 | B2 |
8574216 | Istoc et al. | Nov 2013 | B2 |
8603026 | Favreau | Dec 2013 | B2 |
8603027 | Favreau | Dec 2013 | B2 |
8628510 | Bazargan et al. | Jan 2014 | B2 |
8674288 | Hanson et al. | Mar 2014 | B2 |
8679060 | Mernoe et al. | Mar 2014 | B2 |
8690855 | Alderete, Jr. et al. | Apr 2014 | B2 |
8708961 | Field et al. | Apr 2014 | B2 |
8751237 | Kubota | Jun 2014 | B2 |
8753326 | Chong et al. | Jun 2014 | B2 |
8753331 | Murphy | Jun 2014 | B2 |
8764707 | Moberg et al. | Jul 2014 | B2 |
8764723 | Chong et al. | Jul 2014 | B2 |
8771222 | Kanderian, Jr. et al. | Jul 2014 | B2 |
8777896 | Starkweather et al. | Jul 2014 | B2 |
8777924 | Kanderian, Jr. et al. | Jul 2014 | B2 |
8777925 | Patton | Jul 2014 | B2 |
8784369 | Starkweather et al. | Jul 2014 | B2 |
8784370 | Lebel et al. | Jul 2014 | B2 |
8790295 | Sigg et al. | Jul 2014 | B1 |
8795224 | Starkweather et al. | Aug 2014 | B2 |
8795231 | Chong et al. | Aug 2014 | B2 |
8795260 | Drew | Aug 2014 | B2 |
8801668 | Ali et al. | Aug 2014 | B2 |
8801679 | Iio et al. | Aug 2014 | B2 |
8810394 | Kalpin | Aug 2014 | B2 |
8814379 | Griffiths et al. | Aug 2014 | B2 |
8920374 | Bokelman et al. | Dec 2014 | B2 |
9061104 | Daniel | Jun 2015 | B2 |
9061110 | Avery et al. | Jun 2015 | B2 |
9089475 | Fangrow | Jul 2015 | B2 |
9089641 | Kavazov | Jul 2015 | B2 |
20010025168 | Gross et al. | Sep 2001 | A1 |
20010041869 | Causey et al. | Nov 2001 | A1 |
20020010423 | Gross et al. | Jan 2002 | A1 |
20020029018 | Jeffrey | Mar 2002 | A1 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20020055711 | Lavi et al. | May 2002 | A1 |
20020065488 | Suzuki et al. | May 2002 | A1 |
20020107487 | Preuthun | Aug 2002 | A1 |
20020123740 | Flaherty et al. | Sep 2002 | A1 |
20020161332 | Ramey | Oct 2002 | A1 |
20020169215 | Meng | Nov 2002 | A1 |
20030009133 | Ramey | Jan 2003 | A1 |
20030109827 | Lavi et al. | Jun 2003 | A1 |
20030125671 | Aramata et al. | Jul 2003 | A1 |
20030135159 | Daily et al. | Jul 2003 | A1 |
20030160683 | Blomquist | Aug 2003 | A1 |
20030171717 | Farrugia et al. | Sep 2003 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040015131 | Flaherty et al. | Jan 2004 | A1 |
20040064088 | Gorman et al. | Apr 2004 | A1 |
20040092873 | Moberg | May 2004 | A1 |
20040116866 | Gorman et al. | Jun 2004 | A1 |
20040127857 | Shemesh et al. | Jul 2004 | A1 |
20040158172 | Hancock | Aug 2004 | A1 |
20040186419 | Cho | Sep 2004 | A1 |
20040260233 | Garibotto et al. | Dec 2004 | A1 |
20050033234 | Sadowski et al. | Feb 2005 | A1 |
20050065466 | Vedrine | Mar 2005 | A1 |
20050065472 | Cindrich et al. | Mar 2005 | A1 |
20050071487 | Lu et al. | Mar 2005 | A1 |
20050113761 | Faust et al. | May 2005 | A1 |
20050159706 | Wilkinson et al. | Jul 2005 | A1 |
20050171476 | Judson et al. | Aug 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050177136 | Miller | Aug 2005 | A1 |
20050197650 | Sugimoto et al. | Sep 2005 | A1 |
20050203461 | Flaherty et al. | Sep 2005 | A1 |
20050238507 | DiIanni et al. | Oct 2005 | A1 |
20050283114 | Bresina et al. | Dec 2005 | A1 |
20060013716 | Nason et al. | Jan 2006 | A1 |
20060030816 | Zubry | Feb 2006 | A1 |
20060095014 | Ethelfeld | May 2006 | A1 |
20060122577 | Poulsen et al. | Jun 2006 | A1 |
20060173406 | Hayes et al. | Aug 2006 | A1 |
20060173439 | Thorne et al. | Aug 2006 | A1 |
20060195029 | Shults et al. | Aug 2006 | A1 |
20060211982 | Prestrelski et al. | Sep 2006 | A1 |
20060229569 | Lavi et al. | Oct 2006 | A1 |
20060264889 | Moberg et al. | Nov 2006 | A1 |
20060264890 | Moberg et al. | Nov 2006 | A1 |
20060264894 | Moberg et al. | Nov 2006 | A1 |
20060270987 | Peter | Nov 2006 | A1 |
20060283465 | Nickel et al. | Dec 2006 | A1 |
20060293722 | Slatkine et al. | Dec 2006 | A1 |
20070021733 | Hansen et al. | Jan 2007 | A1 |
20070049865 | Radmer et al. | Mar 2007 | A1 |
20070073228 | Mernoe et al. | Mar 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070167912 | Causey et al. | Jul 2007 | A1 |
20070185449 | Mernoe | Aug 2007 | A1 |
20070197968 | Pongpairochana | Aug 2007 | A1 |
20070203454 | Shermer et al. | Aug 2007 | A1 |
20070233038 | Pruitt et al. | Oct 2007 | A1 |
20070282269 | Carter et al. | Dec 2007 | A1 |
20080021439 | Brittingham et al. | Jan 2008 | A1 |
20080033367 | Haury et al. | Feb 2008 | A1 |
20080033369 | Kohlbrenner et al. | Feb 2008 | A1 |
20080033393 | Edwards et al. | Feb 2008 | A1 |
20080051711 | Mounce et al. | Feb 2008 | A1 |
20080051730 | Bikovsky | Feb 2008 | A1 |
20080059133 | Edwards et al. | Mar 2008 | A1 |
20080097381 | Moberg et al. | Apr 2008 | A1 |
20080108951 | Jerde et al. | May 2008 | A1 |
20080140006 | Eskuri et al. | Jun 2008 | A1 |
20080140018 | Enggaard et al. | Jun 2008 | A1 |
20080147004 | Mann et al. | Jun 2008 | A1 |
20080167641 | Hansen et al. | Jul 2008 | A1 |
20080188813 | Miller et al. | Aug 2008 | A1 |
20080208138 | Lim et al. | Aug 2008 | A1 |
20080215006 | Thorkild | Sep 2008 | A1 |
20080215015 | Cindrich et al. | Sep 2008 | A1 |
20080243087 | Enggaard et al. | Oct 2008 | A1 |
20080249473 | Rutti et al. | Oct 2008 | A1 |
20080262436 | Olson | Oct 2008 | A1 |
20080269687 | Chong et al. | Oct 2008 | A1 |
20080269723 | Mastrototaro et al. | Oct 2008 | A1 |
20080274630 | Shelton et al. | Nov 2008 | A1 |
20080294143 | Tanaka et al. | Nov 2008 | A1 |
20080306449 | Kristensen et al. | Dec 2008 | A1 |
20080312601 | Cane | Dec 2008 | A1 |
20080319416 | Yodfat et al. | Dec 2008 | A1 |
20090041805 | Walker | Feb 2009 | A1 |
20090048347 | Cohen et al. | Feb 2009 | A1 |
20090054750 | Jennewine | Feb 2009 | A1 |
20090069784 | Estes et al. | Mar 2009 | A1 |
20090076453 | Mejlhede et al. | Mar 2009 | A1 |
20090088694 | Carter et al. | Apr 2009 | A1 |
20090088731 | Campbell et al. | Apr 2009 | A1 |
20090093792 | Gross et al. | Apr 2009 | A1 |
20090093793 | Gross et al. | Apr 2009 | A1 |
20090105650 | Wiegel et al. | Apr 2009 | A1 |
20090124977 | Jensen | May 2009 | A1 |
20090143730 | De Polo et al. | Jun 2009 | A1 |
20090143735 | De Polo et al. | Jun 2009 | A1 |
20090149830 | Spector | Jun 2009 | A1 |
20090182277 | Carter | Jul 2009 | A1 |
20090204076 | Liversidge | Aug 2009 | A1 |
20090209896 | Selevan | Aug 2009 | A1 |
20090234319 | Marksteiner | Sep 2009 | A1 |
20090240240 | Hines et al. | Sep 2009 | A1 |
20090253973 | Bashan et al. | Oct 2009 | A1 |
20090259176 | Yairi | Oct 2009 | A1 |
20090281585 | Katzman et al. | Nov 2009 | A1 |
20090299290 | Moberg | Dec 2009 | A1 |
20090299397 | Ruan et al. | Dec 2009 | A1 |
20090326459 | Shipway et al. | Dec 2009 | A1 |
20090326509 | Muse et al. | Dec 2009 | A1 |
20100030156 | Beebe et al. | Feb 2010 | A1 |
20100030198 | Beebe et al. | Feb 2010 | A1 |
20100049128 | McKenzie et al. | Feb 2010 | A1 |
20100049144 | McConnell et al. | Feb 2010 | A1 |
20100057057 | Hayter et al. | Mar 2010 | A1 |
20100076412 | Rush et al. | Mar 2010 | A1 |
20100081993 | O'Connor | Apr 2010 | A1 |
20100094255 | Nycz et al. | Apr 2010 | A1 |
20100100076 | Rush et al. | Apr 2010 | A1 |
20100100077 | Rush et al. | Apr 2010 | A1 |
20100106098 | Atterbury et al. | Apr 2010 | A1 |
20100121314 | Iobbi | May 2010 | A1 |
20100137790 | Yodfat | Jun 2010 | A1 |
20100137831 | Tsals | Jun 2010 | A1 |
20100145303 | Yodfat et al. | Jun 2010 | A1 |
20100145305 | Alon | Jun 2010 | A1 |
20100162548 | Leidig | Jul 2010 | A1 |
20100168607 | Miesel | Jul 2010 | A1 |
20100168683 | Cabiri | Jul 2010 | A1 |
20100198157 | Gyrn et al. | Aug 2010 | A1 |
20100204657 | Yodfat et al. | Aug 2010 | A1 |
20100211011 | Haar | Aug 2010 | A1 |
20100234767 | Sarstedt | Sep 2010 | A1 |
20100234830 | Straessler et al. | Sep 2010 | A1 |
20100241065 | Moberg et al. | Sep 2010 | A1 |
20100264931 | Lindegger et al. | Oct 2010 | A1 |
20100274112 | Hoss et al. | Oct 2010 | A1 |
20100274192 | Mernoe | Oct 2010 | A1 |
20100280499 | Yodfat et al. | Nov 2010 | A1 |
20100331826 | Field et al. | Dec 2010 | A1 |
20110034900 | Yodfat et al. | Feb 2011 | A1 |
20110054399 | Chong et al. | Mar 2011 | A1 |
20110054400 | Chong et al. | Mar 2011 | A1 |
20110066131 | Cabiri | Mar 2011 | A1 |
20110125056 | Merchant | May 2011 | A1 |
20110160654 | Hanson et al. | Jun 2011 | A1 |
20110160666 | Hanson et al. | Jun 2011 | A1 |
20110160669 | Gyrn et al. | Jun 2011 | A1 |
20110172645 | Moga et al. | Jul 2011 | A1 |
20110172745 | Na et al. | Jul 2011 | A1 |
20110178472 | Cabiri | Jul 2011 | A1 |
20110201998 | Pongpairochana et al. | Aug 2011 | A1 |
20110238031 | Adair et al. | Sep 2011 | A1 |
20110245773 | Estes et al. | Oct 2011 | A1 |
20110270160 | Mernoe | Nov 2011 | A1 |
20110282282 | Lorenzen et al. | Nov 2011 | A1 |
20110282296 | Harms et al. | Nov 2011 | A1 |
20110295205 | Kaufmann et al. | Dec 2011 | A1 |
20110313238 | Reichenbach et al. | Dec 2011 | A1 |
20110319861 | Wilk | Dec 2011 | A1 |
20110319919 | Curry et al. | Dec 2011 | A1 |
20120004602 | Hanson et al. | Jan 2012 | A1 |
20120010594 | Holt et al. | Jan 2012 | A1 |
20120022344 | Kube | Jan 2012 | A1 |
20120022499 | Anderson et al. | Jan 2012 | A1 |
20120029431 | Hwang et al. | Feb 2012 | A1 |
20120035546 | Cabiri | Feb 2012 | A1 |
20120041364 | Smith | Feb 2012 | A1 |
20120041414 | Estes et al. | Feb 2012 | A1 |
20120071828 | Tojo et al. | Mar 2012 | A1 |
20120096953 | Bente, IV et al. | Apr 2012 | A1 |
20120096954 | Vazquez et al. | Apr 2012 | A1 |
20120101436 | Bazargan et al. | Apr 2012 | A1 |
20120108933 | Liang et al. | May 2012 | A1 |
20120129362 | Hampo et al. | May 2012 | A1 |
20120160033 | Kow et al. | Jun 2012 | A1 |
20120165733 | Bazargan et al. | Jun 2012 | A1 |
20120165780 | Bazargan et al. | Jun 2012 | A1 |
20120226234 | Bazargan et al. | Sep 2012 | A1 |
20120259282 | Alderete, Jr. et al. | Oct 2012 | A1 |
20130012875 | Gross et al. | Jan 2013 | A1 |
20130068319 | Plumptre et al. | Mar 2013 | A1 |
20130085457 | Schiff et al. | Apr 2013 | A1 |
20130089992 | Yang | Apr 2013 | A1 |
20130096509 | Avery et al. | Apr 2013 | A1 |
20130110049 | Cronenberg et al. | May 2013 | A1 |
20130133438 | Kow et al. | May 2013 | A1 |
20130237953 | Kow et al. | Sep 2013 | A1 |
20130245595 | Kow et al. | Sep 2013 | A1 |
20130245596 | Cabiri et al. | Sep 2013 | A1 |
20130253419 | Favreau | Sep 2013 | A1 |
20130253420 | Favreau | Sep 2013 | A1 |
20130253421 | Favreau | Sep 2013 | A1 |
20130296799 | Degtiar et al. | Nov 2013 | A1 |
20130304021 | Cabiri et al. | Nov 2013 | A1 |
20130323699 | Edwards et al. | Dec 2013 | A1 |
20130331791 | Gross et al. | Dec 2013 | A1 |
20140055073 | Favreau | Feb 2014 | A1 |
20140055076 | Favreau | Feb 2014 | A1 |
20140058349 | Bazargan et al. | Feb 2014 | A1 |
20140083517 | Moia et al. | Mar 2014 | A1 |
20140094755 | Bazargan et al. | Apr 2014 | A1 |
20140128807 | Moberg et al. | May 2014 | A1 |
20140128835 | Moberg et al. | May 2014 | A1 |
20140135692 | Alderete, Jr. et al. | May 2014 | A1 |
20140135694 | Moberg et al. | May 2014 | A1 |
20140142499 | Moberg et al. | May 2014 | A1 |
20140148784 | Anderson et al. | May 2014 | A1 |
20140148785 | Moberg et al. | May 2014 | A1 |
20140163522 | Alderete, Jr. et al. | Jun 2014 | A1 |
20140194819 | Maule et al. | Jul 2014 | A1 |
20140194854 | Tsals | Jul 2014 | A1 |
20140207064 | Yavorsky | Jul 2014 | A1 |
20140207065 | Yavorsky | Jul 2014 | A1 |
20140207066 | Yavorsky | Jul 2014 | A1 |
20140213975 | Clemente et al. | Jul 2014 | A1 |
20140236087 | Alderete, Jr. et al. | Aug 2014 | A1 |
20140261758 | Wlodarczyk et al. | Sep 2014 | A1 |
Number | Date | Country |
---|---|---|
1747683 | Mar 2006 | CN |
1863566 | Nov 2006 | CN |
101090749 | Dec 2007 | CN |
201941304 | Aug 2011 | CN |
102186733 | Sep 2011 | CN |
1064693 | Sep 1959 | DE |
0017412 | Oct 1980 | EP |
0222656 | May 1987 | EP |
0401179 | Dec 1990 | EP |
1530979 | May 2005 | EP |
1666080 | Jun 2006 | EP |
2060606 | May 2009 | EP |
2498589 | Sep 2012 | EP |
H07-194701 | Aug 1995 | JP |
H09-505758 | Jun 1997 | JP |
2001-512992 | Aug 2001 | JP |
2002-505601 | Feb 2002 | JP |
2002-507459 | Mar 2002 | JP |
2002-528676 | Sep 2002 | JP |
2003-501157 | Jan 2003 | JP |
2003-527138 | Sep 2003 | JP |
2003-534061 | Nov 2003 | JP |
2004-501721 | Jan 2004 | JP |
2004-512100 | Apr 2004 | JP |
2005-523127 | Aug 2005 | JP |
2005-270629 | Oct 2005 | JP |
2007-509661 | Apr 2007 | JP |
2008-534131 | Aug 2008 | JP |
2008-220961 | Sep 2008 | JP |
2009-502273 | Jan 2009 | JP |
9009202 | Aug 1990 | WO |
9307922 | Apr 1993 | WO |
9407553 | Apr 1994 | WO |
9513838 | May 1995 | WO |
9609083 | Mar 1996 | WO |
9632975 | Oct 1996 | WO |
9700091 | Jan 1997 | WO |
9710012 | Mar 1997 | WO |
9733638 | Sep 1997 | WO |
9857683 | Dec 1998 | WO |
9929151 | Jun 1999 | WO |
9959665 | Nov 1999 | WO |
0025844 | May 2000 | WO |
0187384 | Nov 2001 | WO |
0189607 | Nov 2001 | WO |
0189613 | Nov 2001 | WO |
0202165 | Jan 2002 | WO |
0234315 | May 2002 | WO |
0272182 | Sep 2002 | WO |
03090833 | Nov 2003 | WO |
2004032990 | Apr 2004 | WO |
2004105841 | Dec 2004 | WO |
2005018703 | Mar 2005 | WO |
2005037350 | Apr 2005 | WO |
2006037434 | Apr 2006 | WO |
2006069380 | Jun 2006 | WO |
2006102676 | Sep 2006 | WO |
2006104806 | Oct 2006 | WO |
2007051563 | May 2007 | WO |
2007056504 | May 2007 | WO |
2008001377 | Jan 2008 | WO |
2008014908 | Feb 2008 | WO |
2008057976 | May 2008 | WO |
2008072229 | Jun 2008 | WO |
2008076459 | Jun 2008 | WO |
2008078318 | Jul 2008 | WO |
2009044401 | Apr 2009 | WO |
2009046989 | Apr 2009 | WO |
2009125398 | Oct 2009 | WO |
2009144085 | Dec 2009 | WO |
2010078227 | Jul 2010 | WO |
2010078242 | Jul 2010 | WO |
2011075105 | Jun 2011 | WO |
2011090955 | Jul 2011 | WO |
2011090956 | Jul 2011 | WO |
2011156373 | Dec 2011 | WO |
2012032411 | Mar 2012 | WO |
2012040528 | Mar 2012 | WO |
WO 2012032411 | Mar 2012 | WO |
2012160157 | Nov 2012 | WO |
2014179774 | Nov 2014 | WO |
Entry |
---|
Office Action issued Jun. 3, 2014 in JP Application No. 2010-527595. |
Office Action issued Jul. 7, 2014 in U.S. Appl. No. 12/244,666 by Gross. |
Int'l Search Report and Written Opinion issued Jul. 31, 2014 in Int'l Application No. PCT/US2014/033598. |
Daikyo Crystal Zenith® polymer, Manufactured by Daikyo Seiko, Ltd. |
Copaxone® , Manufactured by Teva Pharmaceutical Industries Ltd. |
Int'l Search Report issued May 13, 2009 in Int'l Application No. PCT/IL2008/001312. |
Int'l Preliminary Report on Patentability issued Apr. 7, 2010 in Int'l Application No. PCT/IL2008/001312: Written Opinion. |
Int'l Search Report issued Apr. 26, 2010 in Int'l Application No. PCT/US2009/069552. |
Office Action issued Apr. 5, 2010 in U.S. Appl. No. 12/244,666. |
Office Action issued Sep. 21, 2010 in U.S. Appl. No. 12/244,666. |
Office Action issued Apr. 5, 2010 in U.S. Appl. No. 12/244,688. |
Office Action issued Sep. 2, 2010 in U.S. Appl. No. 12/244,688. |
Office Action issued Sep. 30, 2010 in U.S. Appl. No. 12/689,250. |
Int'l Search Report issued Jan. 12, 2011 in Int'l Application No. PCT/US2010/048556; Written Opinion. |
International Preliminary Report on Patentability issued on Jul. 5, 2011 in International Application No. PCT/US2009/069552; Written Opinion. |
Office Action issued Jul. 13, 2011 in U.S. Appl. No. 12/559,563. |
Int'l Preliminary Report on Patentability issued Sep. 1, 2011 in Int'l Application No. PCT/US2010/048556. |
Office Action issued Sep. 6, 2011 in U.S. Appl. No. 12/345,818. |
Office Action issued Feb. 21, 2012 in U.S. Appl. No. 12/689,249. |
Int'l Search Report issued Jun. 17, 2011 in Int'l Application No. PCT/US2011/021604. |
Int'l Search Report issued Oct. 12, 2011 in Int'l Application No. PCT/US2011/021605. |
Office Action issued Oct. 28, 2011 in U.S. Appl. No. 12/615,828. |
Int'l Search Report issued Sep. 22, 2011 in Int'l Application No. PCT/IL11/00368; Written Opinion. |
U.S. Appl. No. 13/521,181 by Cabiri, filed Jul. 9, 2012. |
U.S. Appl. No. 13/521,167 by Cabiri, filed Jul. 9, 2012. |
Office Action issued May 16, 2012 in U.S. Appl. No. 12/615,828. |
Office Action issued Jul. 2, 2012 in U.S. Appl. No. 13/272,555. |
Office Action issued May 3, 2012 in CN Application No. 200880117084.X. |
U.S. Appl. No. 13/472,112 by Cabiri, filed May 15, 2012. |
U.S. Appl. No. 13/429,840 by Cabiri, filed Mar. 26, 2012. |
Int'l Preliminary Report on Patentability issued Aug. 2, 2012 in Int'l Application No. PCT/US2011/021604. |
U.S. Appl. No. 13/643,470 by Alon, filed Oct. 25, 2012. |
Office Action issued Dec. 17, 2013 in JP Application No. 2012-529808. |
Office Action issued Dec. 10, 2013 in CN Application No. 201180006567.4. |
Office Action issued Jan. 8, 2014 in U.S. Appl. No. 13/521,167 by Cabiri. |
U.S. Appl. No. 29/479,307 by Norton, filed Jan. 14, 2014. |
U.S. Appl. No. 14/593,051 by Gross, filed Jan. 9, 2015. |
Office Action issued Jan. 8, 2013 in JP Application No. 2010-527595. |
Int'l Preliminary Report on Patentability issued Feb. 7, 2013 in Int'l Application No. PCT/US2011/021604. |
Int'l Preliminary Report on Patentability issued Feb. 7, 2013 in Int'l Application No. PCT/US2011/021605. |
English translation of an Office Action issued Jan. 30, 2013 in CN Application No. 200880117084.X. |
U.S. Appl. No. 14/193,692 by Gross, filed Feb. 28, 2014. |
Office Action issued Feb. 4, 2014 in EP Application No. 11 707 942.6. |
English translation of an Office Action issued Mar. 5, 2014 in CN Application No. 200880117084.X. |
Int'l Search Report and Written Opinion issued Apr. 3, 2014 in Int'l Application No. PCT/US2013/078040. |
Extended European Search Report issued Mar. 27, 2014 in EP Application No. 14154717.4. |
Office Action issued Feb. 28, 2014 in CN Application No. 201180006571.0. |
Int'l Preliminary Report on Patentability issued May 14, 2015 in Int'l Application No. PCT/US2013/065211. |
Office Action issued May 7, 2015 in JP Application No. 2012-550069. |
Office Action issued May 13, 2015 in CN Application No. 201380025566.3. |
U.S. Appl. No. 14/715,791 by Cabiri, filed May 19, 2015. |
U.S. Appl. No. 14/725,009 by Bar-El, filed May 29, 2015. |
Office Action issued May 1, 2015 in U.S. Appl. No. 14/638,525 by Filman. |
Office Action issued Jun. 4, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
Office Action issued Oct. 9, 2013 in IL Application No. 208634. |
Office Action issued Nov. 5, 2013 in JP Application No. 2010-527595. |
Office Action issued Sep. 29, 2013 in CN Application No. 201080040968.7. |
Office Action issued Nov. 4, 2013 in EP Application No. 11 709 234.6. |
Office Action issued Nov. 5, 2014 in U.S. Appl. No. 13/643,470 by Alon. |
U.S. Appl. No. 14/553,399 by Cabiri, filed Nov. 25, 2014. |
Office Action issued Nov. 2, 2014 in CN Application No. 201180006571.0. |
Office Action issued Nov. 21, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
Office Action issued Nov. 21, 2014 in U.S. Appl. No. 13/429,840 by Cabiri. |
Int'l Preliminary Report on Patentability issued Nov. 27, 2014 in Int'l Application No. PCT/US2013/039465. |
U.S. Appl. No. 13/873,335 by Filman, filed Apr. 30, 2013. |
U.S. Appl. No. 13/892,905 by Cabiri, filed May 13, 2013. |
U.S. Appl. No. 13/874,121 by Degtiar, filed Apr. 30, 2013. |
U.S. Appl. No. 13/874,085 by Cabiri, filed Apr. 30, 2013. |
U.S. Appl. No. 13/874,017 by Cabiri, filed Apr. 30, 2013. |
Extended European Search Report issued Aug. 7, 2014 in EP Application No. 1417477.4. |
Office Action issued Aug. 6, 2014 in EP Application No. 11 707 942.6. |
Office Action issued Sep. 2, 2014 in JP Application No. 2012-550069. |
Office Action issued Sep. 2, 2014 in JP Application No. 2012-550068. |
Office Action issued Aug. 26, 2014 in CN Application No. 201180006567.4. |
Int'l Preliminary Report on Patentability issued Oct. 9, 2014 in Int'l Application No. PCT/US2013/033118. |
Office Action issued Oct. 9, 2014 in U.S. Appl. No. 13/873,335. |
Int'l Search Report and Written Opinion issued Jul. 26, 2013 in Int'l Application No. PCT/US2012/039465. |
Int'l Search Report and Written Opinion issued Aug. 5, 2013 in Int'l Application No. PCT/US2013/033118. |
U.S. Appl. No. 13/964,651 by Gross, filed Aug. 12, 2013. |
Office Action issued Aug. 15, 2013 in CN Application No. 200880117084.X. |
Office Action issued Jul. 31, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
Office Action issued Aug. 13, 2015 in U.S. Appl. No. 14/553,399 by Cabiri. |
Int'l Preliminary Report on Patentability issued Jul. 16, 2015 in Int'l Application No. PCT/US2013/078040. |
Notice of Allowance issued Aug. 24, 2015 in U.S. Appl. No. 29/479,307 by Norton. |
U.S. Appl. No. 14/258,661 by Cabiri, filed Apr. 22, 2014. |
Int'l Search Report and Written Opinion issued Jan. 7, 2014 in Int'l Application No. PCT/US2013/065211. |
Office Action issued May 23, 2014 in U.S. Appl. No. 13/472,112 by Cabiri. |
U.S. Appl. No. 14/683,193 by Cabiri, filed Apr. 10, 2015. |
Office Action issued Feb. 20, 2015 in U.S. Appl. No. 13/521,181 by Cabiri. |
Office Action issued Feb. 24, 2015 in U.S. Appl. No. 14/258,661 by Cabiri. |
U.S. Appl. No. 14/638,525 by Filman, filed Mar. 4, 2015. |
Extended European Search Report issued Feb. 23, 2015 in EP Application No. 14166596.8. |
Office Action issued Mar. 10, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
Office Action issued Mar. 10, 2015 in U.S. Appl. No. 12/244,666 by Gross. |
Extended European Search Report issued Feb. 23, 2015 in EP Application No. 14166591.9. |
Office Action issued Mar. 10, 2015 in CN Application No. 201180006567.4. |
Office Action issued Mar. 31, 2015 in JP Application No. 2012-550068. |
Office Action issued Jan. 4, 2016 in U.S. Appl. No. 13/892,905 by Cabiri. |
Office Action issued Sep. 9, 2015 in U.S. Appl. No. 13/643,470 by Alon. |
U.S. Appl. No. 14/850,450 by Gross, filed Sep. 10, 2015. |
U.S. Appl. No. 14/861,478 by Cabiri, filed Sep. 22, 2015. |
U.S. Appl. No. 14/880,673 by Cabiri, filed Oct. 12, 2015. |
Office Action issued Sep. 30, 2015 in U.S. Appl. No. 13/667,739 by Cabiri. |
Office Action issued Sep. 18, 2015 in U.S. Appl. No. 13/874,085 by Cabiri. |
U.S. Appl. No. 15/196,775 by Cabiri, filed Jun. 29, 2016. |
Office Action issued Jul. 7, 2016 in U.S. Appl. No. 13/892,905 by Cabiri. |
Number | Date | Country | |
---|---|---|---|
20140188073 A1 | Jul 2014 | US |